Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in sei
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started tre
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
02:03pm, Wednesday, 03'rd Dec 2025
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Biogen Inc. $BIIB Stake Reduced by Fisher Asset Management LLC
04:34am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC decreased its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 3.3% in the undefined quarter, according to the company in its most recent filing with the Securities and
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
03:43pm, Tuesday, 02'nd Dec 2025
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
07:30am, Monday, 01'st Dec 2025
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
07:30am, Monday, 01'st Dec 2025
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potenti
Biogen shares could climb on Leqembi uptake – Jefferies
09:46am, Friday, 28'th Nov 2025
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer's drug Leqembi and a series of late-stage pipeline readouts draw more investor
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
07:30pm, Thursday, 27'th Nov 2025
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved,
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
11:46am, Tuesday, 25'th Nov 2025
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this
Market Today: Alphabet rallies, Amazon's $50B AI push
05:35pm, Monday, 24'th Nov 2025
Guru Stock PicksElfun Trusts has made the following transactions:Reduce in MLM by 7.18%Sold out in KVUEAdd in TXN by 36.84%New position in AMDStock News Tech-le
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
11:17am, Monday, 24'th Nov 2025
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-st
Novo Nordisk's Alzheimer's Trials Disappoint, Impacting Stock Performance
11:14am, Monday, 24'th Nov 2025
Novo Nordisk (NVO) shares are dropping after the company announced that its Phase 3 EVOKE and EVOKE+ trials of oral semaglutide failed to show a statistically s
